| 10/17/08 |
Sirtris to Present at First Annual Boston Biotech R&D Conference |
| 10/16/08 |
Sirtris CEO Christoph Westphal Selected by Biotech CEOs as Outstanding Individual |
| 10/01/08 |
Sirtris’ Review of Sirtuin Therapeutics for Diseases of Aging in the Journal Nature Reviews Drug Discovery |
| 09/16/08 |
Sirtris Completes Exclusive License to Harvard's SIRT3-Based Intellectual Property |
| 07/03/08 |
Long-Term Study of Middle-Aged Mice Shows Resveratrol Improves Health and Mimics Some Benefits of Dietary Restriction |
| 06/04/08 |
Sirtris Pharmaceuticals Presents at the American Diabetes Association’s 68th Annual Scientific Sessions June 8 |
| 06/02/08 |
GlaxoSmithKline Successfully Completes Tender Offer for Shares of Sirtris Pharmaceuticals |
| 05/02/08 |
GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals |
| 05/01/08 |
Sirtris Pharmaceuticals Reports First Quarter 2008 Financial Results |
| 04/22/08 |
GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development |
| 04/17/08 |
Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics |
| 04/16/08 |
Sirtris Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development |
| 04/02/08 |
Sirtris Receives Orphan Drug Designation from U.S. Food and Drug Administration for Resveratrol in Mitochondrial Disorder, MELAS Syndrome |
| 04/02/08 |
Sirtris Receives Orphan Drug Designation from U.S. Food and Drug Administration for Resveratrol in Mitochondrial Disorder, MELAS Syndrome |
| 04/01/08 |
Sirtris Pharmaceuticals Presents at American Chemical Society April 7 |
| 03/28/08 |
Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model |
| 03/25/08 |
Sirtris Pharmaceuticals Announces the Appointment of Paul A. Friedman, M.D., President and CEO of Incyte Corporation, to its Board of Directors |
| 03/24/08 |
Sirtris Pharmaceuticals Presents at Future Leaders in the Biotechnology Industry Conference March 27 |
| 03/19/08 |
Sirtris Announces First U.S. Patent Issued On Class of SIRT1 Activators; Patent Covers First NCE to Enter Human Clinical Trials |
| 03/13/08 |
Sirtris Pharmaceuticals Presents at Cowen and Company Health Care Conference & the IBC Life Sciences Metabolic Disorders Conference on March 18 |
| 03/12/08 |
Sirtris Pharmaceuticals Sublicenses Portion of Lifespan Technology in Plants to Bayer CropScience AG |
| 03/11/08 |
Sirtris Pharmaceuticals In-Licenses Key Genetic Driver of Cellular Stress Resistance and Longevity in Mammals from Robarts Research Institute |
| 03/10/08 |
Sirtris Pharmaceuticals Collaborator Presents Neuroprotective Data for Oral Drug Candidate SRT501 at North American Neuro-Ophthalmology Society Meeting |
| 03/04/08 |
Sirtris Pharmaceuticals' SRT501 Slows Retinal Ganglion Cell Loss During Optic Neuritis in a Preclinical Model of Multiple Sclerosis |
| 02/25/08 |
Sirtris Pharmaceuticals Reports Fourth Quarter and 2007 Financial Results; Significant Progress Achieved |
| 02/21/08 |
Sirtris Pharmaceuticals Enters Collaborative Study Testing New Chemical Entities and Clinical Drug Candidate In Multiple Models of Cancer with the National Cancer Institute |
| 02/20/08 |
Sirtris Pharmaceuticals Co-Founder Presents First In-Vivo, Preclinical Data Showing SIRT1 Activation Can Suppress Tumor Formation and Growth |
| 02/12/08 |
Sirtris Pharmaceuticals to Webcast Conference Call for Fiscal 2007 Financial Results |
| 02/07/08 |
Sirtris Pharmaceuticals to Present at the BIO CEO & Investor Conference February 12 |
| 02/05/08 |
Leonard P. Guarente, a Founder of the Sirtuin Field, Signs Exclusive Consulting Agreement with Sirtris Pharmaceuticals |
| 01/31/08 |
Sirtris Pharmaceuticals to Present at the 15th Annual Emerald Asset Management Investment Forum February 7 |
| 01/24/08 |
Sirtris Pharmaceuticals: Novel, Potent SIRT1 Activator Reduces Fat, Boosts Endurance and Improves Insulin Sensitivity in a Pre-clinical Model of Type 2 Diabetes |
| 01/23/08 |
Sirtris Pharmaceuticals to Present at Keystone Symposia's Diabetes Mellitus, Insulin Action and Resistance Conference |
| 01/22/08 |
Sirtris Pharmaceuticals CEO Presents Keynote Address at the Charite Hospital Berlin, Europe's Leading University Hospital |
| 01/07/08 |
Sirtris Announces Positive Results with Proprietary Version of Resveratrol, SRT501, in a Phase 1b Type 2 Diabetes Clinical Study |
| 01/03/08 |
Sirtris Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference January 7, 2008 |
| 01/02/08 |
Sirtris Pharmaceuticals Announces the Appointment of Jeffrey Capello, SVP and CFO of PerkinElmer, to its Board of Directors |
